The city of Boston, Massachusetts, currently has 468 active clinical trials seeking participants for Cancer research studies.
ART-Pro: Clinical Trial Evaluating Biparametric MRI and Advanced, Quantitative Diffusion MRI for Detection of Prostate Cancer
Recruiting
This is a multicenter, multinational trial to evaluate advanced MRI techniques for improved detection of clinically significant prostate cancer (csPCa). The study will enroll 500 participants at 5 clinical centers (100 participants per center). The current standard MRI technique for prostate cancer screening is multiparametric MRI (mpMRI), but two drawbacks include need for intravenous (IV) contrast and dependence on radiologist expertise. The investigators expect that the combination of two oth... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
11/04/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Prostate Cancer
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
Recruiting
The goal of this research study is to evaluate the safety and effectiveness of the use of cytokine-induced memory-like (CIML) natural killer (NK) cell therapy in recurrent, high grade ovarian cancer (HGOC). Names of the study therapies involved in this study are: CIML NK (cellular therapy) Interleukin-2 (IL-2)
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
10/30/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Platinum-resistant Ovarian Cancer, Recurrent Ovary Cancer, Ovarian Cancer, Ovarian Carcinoma, Ovarian Carcinoma, Recurrent
ALPINE: Maintenance Letrozole/Abemaciclib Vs Pembrolizumab
Recruiting
A standard treatment for endometrial cancer is chemotherapy and pembrolizumab together followed by pembrolizumab maintenance for two years. This treatment regimen has shown benefit in terms of delaying cancer progression in prior clinical trials, but the benefit of the pembrolizumab maintenance treatment and whether all participants need it is unclear. This research is being done on the maintenance portion of treatment to compare the efficacy between the combination of letrozole + abemaciclib an... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts +2 locations
Conditions: Endometrial Cancer, Recurrent Endometrial Cancer, TP53
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Recruiting
The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.
Gender:
ALL
Ages:
Between 18 years and 39 years
Trial Updated:
10/28/2024
Locations: Tufts Medical Center, Boston, Massachusetts
Conditions: Breast Cancer, NOS, CNS Primary Tumor, NOS, Cervical Cancer, NOS, Colorectal Cancer, NOS, Leukemia, NOS, Lymphoma, NOS, Miscellaneous Neoplasm, NOS, Non-Rhabdomyosarcoma Soft Tissue Sarcoma, NOS, Testicular Nonseminomatous Germ Cell Tumor, NOS, Thyroid Cancer, NOS, Melanoma, Bone Cancer, NOS
Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity
Recruiting
This study is about testing whether exercise will improve fitness and lessen risk factors related to heart disease, diabetes, and obesity in Latina breast cancer survivors.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/28/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Breast Cancer, Coronary Artery Disease, Stroke, Type2 Diabetes
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
Recruiting
This research study is studying the usefulness of magnetic resonance imaging (MRI) to screen for brain metastases (spread of the breast cancer to the brain).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/22/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Inflammatory Breast Cancer, Metastatic Breast Cancer
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
Recruiting
The purpose of this study is to determine whether AGuIX (Activation and Guidance of Irradiation by X-ray) gadolinium-based nanoparticles make radiation work more effectively in the treatment of patients with brain metastases that are more difficult to control with stereotactic radiation alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/22/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Brain Cancer, Brain Metastases, Melanoma, Lung Cancer, Breast Cancer, HER2-positive Breast Cancer, Colorectal Cancer, Gastrointestinal Cancer, SRS, SRT, Whole Brain Radiation, Stereotactic Radiation, AGuIX, Nanoparticle, Cystic, Brain Tumor
Biology of Young Lung Cancer Study: The YOUNG LUNG Study
Recruiting
The purpose of this research study is to learn more about lung cancer (NSCLC or SCLC) diagnosed in adults at ages 45 or younger.
Gender:
ALL
Ages:
Between 15 years and 45 years
Trial Updated:
10/21/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +3 locations
Conditions: Non Small Cell Lung Cancer, Small Cell Lung Carcinoma, NUT Carcinoma
Phase I/II Trial of Pembrolizumab and Androgen-receptor Pathway Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
Recruiting
This is a phase I/II study investigating the combination of 225Ac-J591 (a drug that can deliver radiation to prostate cancer cells) with pembrolizumab (immunotherapy, a drug that increases the immune system's ability to destroy cancer cells). This study will assess whether 225Ac-J591 + pembrolizumab + androgen receptor pathway inhibitor (ARPI) is more effective against prostate cancer than pembrolizumab + ARPI alone.
Gender:
MALE
Ages:
Between 18 years and 99 years
Trial Updated:
10/15/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Prostate Cancer
Psilocybin in Cancer Pain Study
Recruiting
The overall objective of this study is to assess the feasibility, safety and preliminary efficacy of psilocybin-assisted therapy to alleviate opioid-refractory pain in patients with advanced-cancer. The name of the study intervention used in this research study is: Psilocybin (a tryptamine derivative)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/14/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Opioid-Related Disorders, Pain Management, Pain Management and Care, Advanced Cancer, Advanced Cancers
Prostate Cancer Genetic Risk Evaluation and Screening Study
Recruiting
This study aims to define the natural history of men at high genetic risk for prostate cancer on the basis of specific germline genetic mutations, family history, or Black/African ancestry and evaluate the utility of prostate MRI as a screening tool. The hypothesis is that this targeted population of men are at elevated risk of developing prostate cancer compared to the general population, and enhanced screening with MRI will enable early detection and diagnosis of potentially aggressive prostat... Read More
Gender:
MALE
Ages:
Between 35 years and 74 years
Trial Updated:
10/05/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Prostatic Neoplasm, Prostate Cancer, BRCA2 Mutation, BRCA1 Mutation, ATM Gene Mutation, MMR Mutation, Lynch Syndrome, Genetic Predisposition to Disease
Prolonged Overnight Fasting And/or Exercise on Fatigue and Other Patient Reported Outcomes in Women with Hormone Receptor Positive Advanced Breast Cancer
Recruiting
The purpose of this study is to test if four different programs (prolonged overnighting fasting alone, exercise alone, a combination of prolonged overnight fasting and exercise, or general health education sessions alone) can reduce fatigue in women with advanced or metastatic breast cancer who are receiving a medication called a cyclin-dependent kinases-4 and 6 (CDK4/6) inhibitor.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/03/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: HER2-positive Breast Cancer, Advanced Breast Cancer